LVTX vs. CNTX, GRFS, MYNZ, NLSP, PHVS, TLSA, ATNFW, SXTPW, ACONW, and AIMDW
Should you be buying LAVA Therapeutics stock or one of its competitors? The main competitors of LAVA Therapeutics include Context Therapeutics (CNTX), Grifols (GRFS), Mainz Biomed (MYNZ), NLS Pharmaceutics (NLSP), Pharvaris (PHVS), Tiziana Life Sciences (TLSA), 180 Life Sciences (ATNFW), 60 Degrees Pharmaceuticals (SXTPW), Aclarion (ACONW), and Ainos (AIMDW). These companies are all part of the "medical" sector.
Context Therapeutics (NASDAQ:CNTX) and LAVA Therapeutics (NASDAQ:LVTX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, community ranking, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.
Context Therapeutics has a beta of 2.14, meaning that its stock price is 114% more volatile than the S&P 500. Comparatively, LAVA Therapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500.
LAVA Therapeutics received 12 more outperform votes than Context Therapeutics when rated by MarketBeat users. Likewise, 75.86% of users gave LAVA Therapeutics an outperform vote while only 58.82% of users gave Context Therapeutics an outperform vote.
In the previous week, Context Therapeutics had 3 more articles in the media than LAVA Therapeutics. MarketBeat recorded 5 mentions for Context Therapeutics and 2 mentions for LAVA Therapeutics. LAVA Therapeutics' average media sentiment score of 0.01 beat Context Therapeutics' score of 0.00 indicating that Context Therapeutics is being referred to more favorably in the media.
Context Therapeutics currently has a consensus target price of $4.00, indicating a potential upside of 112.77%. LAVA Therapeutics has a consensus target price of $6.00, indicating a potential upside of 98.02%. Given LAVA Therapeutics' higher probable upside, analysts plainly believe Context Therapeutics is more favorable than LAVA Therapeutics.
14.0% of Context Therapeutics shares are held by institutional investors. 9.4% of Context Therapeutics shares are held by insiders. Comparatively, 0.8% of LAVA Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Context Therapeutics has a net margin of 0.00% compared to Context Therapeutics' net margin of -620.09%. Context Therapeutics' return on equity of -68.54% beat LAVA Therapeutics' return on equity.
Context Therapeutics has higher earnings, but lower revenue than LAVA Therapeutics. LAVA Therapeutics is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Context Therapeutics beats LAVA Therapeutics on 10 of the 15 factors compared between the two stocks.
Get LAVA Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LVTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
LAVA Therapeutics Competitors List
Related Companies and Tools
